Skip to main content

Table 3 Diagnostic test statistics of the study cohort showing the accuracy and missed cancer rates for each phi threshold as a triage test pre-MRI and biopsy. PSAd thresholds are shown as a comparator though this metric is not usually available before an mpMRI. Detection rates for cancer are shown using definitions of ≥ Grade Group 2 (GG2) or ≥ Cambridge Prognostic Group 3 [CPG3]. (*percentage out of 258 cancers detected, ** percentage out of 176 cancers detected)

From: Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study

 ≥ GG2 cancer detection≥ CPG3 cancer detection
ThresholdSensitivitySpecificityNPV% cancers missed*SensitivitySpecificityNPV% cancers missed**
phi200.990.100.901.11.000.081.000
250.960.250.874.20.990.220.990.05
300.920.400.857.70.950.350.941.0
350.870.550.8312.80.930.490.937.3
PSAd0.100.930.310.827.30.970.280.952.8
0.150.810.570.7718.60.900.530.929.6
0.200.690.770.7331.30.800.720.8820.0